Vorasidenib-VORANIGO market price and drug purchase reference instructions

Vorasidenib (trade name VORANIGO) is currently not on the market in China and is not included in medical insurance. Therefore, domestic patients cannot purchase it directly through regular hospital pharmacies for the time being. The use of this drug can almost only rely on special import channels or participation in clinical trials, and the out-of-pocket costs need to be borne by the patient. The lack of formal sales channels in the country means that drug accessibility and regulation are incomplete, and patients need to be extra cautious when obtaining drugs.

In overseas markets, the price of the original drug Voxanib is very high. Taking the US version of the original drug as an example, the specification is 40mg The high price is mainly due to its innovative targeting mechanism and R&D costs. At the same time, actual costs may fluctuate slightly in different countries and regions due to differences in exchange rates, import taxes, and channels. For patients with limited financial conditions, using original drugs requires a full assessment of budget and affordability.

There are also generic versions of the drug sold overseas, and their drug ingredients are basically the same as those of the original drug. For example, voxanib of the same specification produced by Lucius Pharmaceuticals in Laos sells for about more than 7,000 yuan per box. Compared with original drugs, generic drugs are more affordable and provide patients with certain economic relief. However, when choosing generic drugs, you need to pay attention to the formality of drug sources and quality reliability, and avoid purchasing drugs through illegal channels to ensure drug safety.

Patients should strictly follow the doctor's instructions when using voroxiranib, including pre-medication IDH1/IDH2 mutation detection, liver and kidney function assessment, and regular monitoring during medication. In the future, with the advancement of domestic drug approval and import policies, Voxiranib is expected to enter the domestic market and be included in the medical insurance system. By then, patients can purchase it through formal channels and enjoy reimbursement benefits. For now, patients should pay attention to official information, choose drug sources carefully, and be financially and safely prepared.

Reference materials:https://www.drugs.com/